NLM Digital Collections

Search

Start Over Subjects Orphan Drug Production -- economics ✖Remove constraint Subjects: Orphan Drug Production -- economics

1. Assessing user fees under the Prescription Drug User Fee Amendments of 2017

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, May 2018
Subject(s):
Fees and Charges
Investigational New Drug Application -- economics
Prescription Drugs -- economics
Biological Products -- economics
Orphan Drug Production -- economics
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

2. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, November 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)

3. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

4. High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2021
Subject(s):
Drug Development -- legislation & jurisprudence
Government Regulation
Medicare Part B -- economics
Medicare Part D -- economics
Orphan Drug Production -- economics
United States
United States. Department of Health and Human Services

5. Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, October 2019
Subject(s):
Drug Approval -- economics
Drug Approval -- legislation & jurisprudence
Investigational New Drug Application -- legislation & jurisprudence
Diffusion of Innovation
Economics, Pharmaceutical
Orphan Drug Production -- economics
Public Health
Small Business
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

6. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

7. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States